{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T19:22:25Z","timestamp":1794943345733,"version":"4.9.1"},"reference-count":36,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020999","name":"Bio Farma Persero PT","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020999","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.vaccine.2024.03.077","type":"journal-article","created":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T08:39:13Z","timestamp":1712219953000},"page":"3009-3017","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Immunogenicity and safety of SARS-CoV-2 recombinant protein subunit vaccine (IndoVac) adjuvanted with alum and CpG 1018 in Indonesian adults: A phase 3, randomized, active-controlled, multicenter trial"],"prefix":"10.1016","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0346-2337","authenticated-orcid":false,"given":"Asrawati","family":"Nurdin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yetty","family":"Movieta Nency","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6109-6024","authenticated-orcid":false,"given":"Martira","family":"Maddeppungeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rini","family":"Sekartini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rini","family":"Mulia Sari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5089-3113","authenticated-orcid":false,"given":"Fikrianti","family":"Surachman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Finny","family":"Fitry Yani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Raveinal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fenty","family":"Anggrainy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2587-0849","authenticated-orcid":false,"given":"Al","family":"Hafiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Linosefa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rizanda","family":"Machmud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Putri","family":"Awaliyah Deza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1987-2662","authenticated-orcid":false,"given":"Vovinda","family":"Rujiana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martga","family":"Bella Rahimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7385-3325","authenticated-orcid":false,"given":"Nur","family":"Farhanah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Setyo","family":"Gundi Pramudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8367-063X","authenticated-orcid":false,"given":"Rebriarina","family":"Hapsari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimas","family":"Tri Anantyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Mulyono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9101-8753","authenticated-orcid":false,"given":"Endang","family":"Mahati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5984-6439","authenticated-orcid":false,"given":"Nani","family":"Maharani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9560-5229","authenticated-orcid":false,"given":"Sidrah","family":"Darma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andi","family":"Husni Esa Darussalam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharifah","family":"Shakinah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Nasrum Massi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Soedjatmiko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2024.03.077_b0005","unstructured":"World Health Organization Indonesia. Coronavirus disease 2019 (COVID-19) situation report \u2013 53. 2020. Accessed: Apr. 30, 2021. [Online]. Available: https:\/\/www.who.int\/publications\/m\/item\/situation-report---53."},{"key":"10.1016\/j.vaccine.2024.03.077_b0010","doi-asserted-by":"crossref","unstructured":"Hotezid PJ, Bottazziid ME. Developing a low-cost and accessible COVID-19 vaccine for global health; 2020, doi: 10.1371\/journal.pntd.0008548.","DOI":"10.1371\/journal.pntd.0008548"},{"key":"10.1016\/j.vaccine.2024.03.077_b0015","unstructured":"Fujiwara Y, Raine J. ICMRA COVID-19 vaccine development: future steps workshop. Accessed: Mar. 24, 2022. [Online]. Available: https:\/\/www.icmra.info\/drupal\/en\/covid-19\/24june2021."},{"key":"10.1016\/j.vaccine.2024.03.077_b0020","unstructured":"World Health Organization. Considerations for the assessment of COVID-19 vaccines for listing by WHO (version 30 March 2022), Mar. 30, 2022."},{"key":"10.1016\/j.vaccine.2024.03.077_b0025","unstructured":"Ministry of Health Republic of Indonesia, \u201cHasil sero survey\u00a0: 86,6% penduduk Indonesia memiliki antibodi terhadap COVID-19,\u201d 2022. Accessed: Mar. 24, 2022. [Online]. Available: https:\/\/sehatnegeriku.kemkes.go.id\/baca\/rilis-media\/penelitian-dan-pengembangan-kesehatan\/20220318\/3139545\/hasil-sero-survey-866-penduduk-indonesia-memiliki-antibodi-terhadap-covid-19\/."},{"issue":"31","key":"10.1016\/j.vaccine.2024.03.077_b0030","doi-asserted-by":"crossref","first-page":"988","DOI":"10.15585\/mmwr.mm7131a2","article-title":"Interim recommendation of the advisory committee on immunization practices for use of the novavax COVID-19 vaccine in persons aged \u226518 years \u2014 United States, july 2022","volume":"71","author":"Twentyman","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2024.03.077_b0035","unstructured":"Novavax. Novavax announces extended durability of protection against infection and disease in United Kingdom COVID-19 vaccine phase 3 clinical trial. Accessed: Mar. 24, 2022. [Online]. Available: https:\/\/ir.novavax.com\/press-releases\/2022-02-28-Novavax-Announces-Extended-Durability-of-Protection-Against-Infection-and-Disease-in-United-Kingdom-COVID-19-Vaccine-Phase-3-Clinical-Trial."},{"issue":"47","key":"10.1016\/j.vaccine.2024.03.077_b0040","doi-asserted-by":"crossref","first-page":"7533","DOI":"10.1016\/j.vaccine.2020.09.061","article-title":"Yeast-expressed SARS-CoV recombinant receptor-binding domain (RBD219-N1) formulated with aluminum hydroxide induces protective immunity and reduces immune enhancement","volume":"38","author":"Chen","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.03.077_b0045","unstructured":"World Health Organization, Polio Laboratory Manual, 4th Edition; 2004."},{"key":"10.1016\/j.vaccine.2024.03.077_b0050","unstructured":"National Institute for Biological Standards and Control. Working standard working reagent for anti-SARS-CoV-2 immunoglobulin NIBSC code: 21\/234. 2021. Accessed: Mar. 01, 2024. [Online]. Available: https:\/\/www.nibsc.org\/documents\/ifu\/21-234.pdf."},{"key":"10.1016\/j.vaccine.2024.03.077_b0055","unstructured":"World Health Organization, Causality assessment of an adverse event following immunization (AEFI): user manual for the revised WHO classification, 2nd Edition. 2019."},{"key":"10.1016\/j.vaccine.2024.03.077_b0060","unstructured":"World Health Organization, COVID-19 vaccines: safety surveillance manual - Monitoring and responding to adverse events of special interest. 2020."},{"key":"10.1016\/j.vaccine.2024.03.077_b0065","unstructured":"Indonesian Society of Respirology, Indonesian Society of Internal Medicine, Indonesian Heart Association, Indonesian Society of Anesthesiologists and Intensive Therapy, and Indonesian Pediatric Society, COVID-19 management guideline, 4th Edition. 2022."},{"issue":"6494","key":"10.1016\/j.vaccine.2024.03.077_b0070","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1126\/science.abb8923","article-title":"Rapid COVID-19 vaccine development","volume":"368","author":"Graham","year":"2020","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.vaccine.2024.03.077_b0075","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-77077-z","article-title":"Development of CpG-adjuvanted stable prefusion SARS-CoV-2 spike antigen as a subunit vaccine against COVID-19","volume":"10","author":"Kuo","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2024.03.077_b0080","doi-asserted-by":"crossref","unstructured":"Liu L. et al., Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 2020 584:7821, vol. 584, no. 7821, pp. 450\u2013456, Jul. 2020, doi: 10.1038\/s41586-020-2571-7.","DOI":"10.1038\/s41586-020-2571-7"},{"issue":"6506","key":"10.1016\/j.vaccine.2024.03.077_b0085","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1126\/science.abd0827","article-title":"Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail","volume":"369","author":"Hansen","year":"2020","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.vaccine.2024.03.077_b0090","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1016\/j.cell.2021.02.035","article-title":"Extremely potent human monoclonal antibodies from COVID-19 convalescent patients","volume":"184","author":"Andreano","year":"2021","journal-title":"Cell"},{"issue":"6504","key":"10.1016\/j.vaccine.2024.03.077_b0095","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1126\/science.abc5902","article-title":"Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability","volume":"369","author":"Brouwer","year":"2020","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.vaccine.2024.03.077_b0100","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1016\/j.cell.2021.02.032","article-title":"The antigenic anatomy of SARS-CoV-2 receptor binding domain","volume":"184","author":"Dejnirattisai","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2024.03.077_b0105","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.coi.2020.08.008","article-title":"New horizons in adjuvants for vaccine development","volume":"65","author":"Reed","year":"2020","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.vaccine.2024.03.077_b0110","doi-asserted-by":"crossref","unstructured":"Pulendran B, Arunachalam PS, O\u2019Hagan DT. Emerging concepts in the science of vaccine adjuvants. Nat Rev Drug Discovery 2021 20:6, vol. 20, no. 6, pp. 454\u2013475, Apr. 2021, doi: 10.1038\/s41573-021-00163-y.","DOI":"10.1038\/s41573-021-00163-y"},{"key":"10.1016\/j.vaccine.2024.03.077_b0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2020.101426","article-title":"The continued advance of vaccine adjuvants - \u2018we can work it out\u2019","volume":"50","author":"O\u2019Hagan","year":"2020","journal-title":"Semin Immunol"},{"issue":"629","key":"10.1016\/j.vaccine.2024.03.077_b0120","doi-asserted-by":"crossref","first-page":"5305","DOI":"10.1126\/scitranslmed.abj5305","article-title":"An aluminum hydroxide:CpG adjuvant enhances protection elicited by a SARS-CoV-2 receptor binding domain vaccine in aged mice","volume":"14","author":"Nanishi","year":"2022","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.vaccine.2024.03.077_b0125","doi-asserted-by":"crossref","first-page":"e52","DOI":"10.1016\/S2666-5247(21)00267-6","article-title":"Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis","volume":"3","author":"Cromer","year":"2022","journal-title":"Lancet Microbe"},{"issue":"24","key":"10.1016\/j.vaccine.2024.03.077_b0130","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1056\/NEJMoa2026920","article-title":"Phase 1\u20132 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine","volume":"383","author":"Keech","year":"2020","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.vaccine.2024.03.077_b0135","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1056\/NEJMoa2107659","article-title":"Safety and efficacy of NVX-CoV2373 COVID-19 vaccine","volume":"385","author":"Heath","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2024.03.077_b0140","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2022.927306","article-title":"A comprehensive review of the protein subunit vaccines against COVID-19","volume":"13","author":"Heidary","year":"2022","journal-title":"Front Microbiol"},{"key":"10.1016\/j.vaccine.2024.03.077_b0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.lansea.2022.100139","article-title":"Safety and immunogenicity of SII-NVX-CoV2373 (COVID-19 vaccine) in adults in a phase 2\/3, observer-blind, randomised, controlled study","volume":"10","author":"Kulkarni","year":"2023","journal-title":"The Lancet Regional Health - Southeast Asia"},{"issue":"1","key":"10.1016\/j.vaccine.2024.03.077_b0150","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2023.2203632","article-title":"Immunogenicity and safety of biological e\u2019s CORBEVAXTM vaccine compared to COVISHIELDTM (ChAdOx1 nCoV-19) vaccine studied in a phase-3, single blind, multicentre, randomized clinical trial","volume":"19","author":"Thuluva","year":"2023","journal-title":"Hum Vaccin Immunother"},{"issue":"11","key":"10.1016\/j.vaccine.2024.03.077_b0155","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1016\/j.vaccine.2023.02.017","article-title":"Immunogenicity of an adjuvanted SARS-CoV-2 trimeric S-protein subunit vaccine (SCB-2019) in SARS-CoV-2-na\u00efve and exposed individuals in a phase 2\/3, double-blind, randomized study","volume":"41","author":"Buntinx","year":"2023","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2024.03.077_b0160","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2023.2301632","article-title":"SCB-2019 protein vaccine as heterologous booster of neutralizing activity against SARS-CoV-2 omicron variants after immunization with other COVID-19 vaccines","volume":"20","author":"Roa","year":"2024","journal-title":"Hum Vaccin Immunother"},{"issue":"9","key":"10.1016\/j.vaccine.2024.03.077_b0165","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1093\/infdis\/jiad262","article-title":"Superior boosting of neutralizing titers against omicron SARS-CoV-2 variants by heterologous SCB-2019 vaccine vs a homologous booster in CoronaVac-primed adults","volume":"228","author":"Roa","year":"2023","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2024.03.077_b0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcv.2022.105321","article-title":"NVX-CoV2373-induced cellular and humoral immunity towards parental SARS-CoV-2 and VOCs compared to BNT162b2 and mRNA-1273-regimens","volume":"157","author":"Hielscher","year":"2022","journal-title":"J Clin Virol"},{"key":"10.1016\/j.vaccine.2024.03.077_b0175","doi-asserted-by":"crossref","unstructured":"Petrovsky N. Comparative safety of vaccine adjuvants: a summary of current evidence and future needs. Drug Safety 2015 38:11, vol. 38, no. 11, pp. 1059\u20131074, Oct. 2015, doi: 10.1007\/S40264-015-0350-4.","DOI":"10.1007\/s40264-015-0350-4"},{"key":"10.1016\/j.vaccine.2024.03.077_b0180","unstructured":"BPS-Statistics Indonesia, Mortality in Indonesia: the results of population census 2020. 2020."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24003992?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24003992?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T05:55:23Z","timestamp":1725688523000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X24003992"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":36,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S0264410X24003992"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.03.077","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenicity and safety of SARS-CoV-2 recombinant protein subunit vaccine (IndoVac) adjuvanted with alum and CpG 1018 in Indonesian adults: A phase 3, randomized, active-controlled, multicenter trial","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.03.077","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}